Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases.
Krm2-deficient mice being older than one year, and it may be worthwhile to analyze the possibility that these mice are protected from tumor-induced osteolytic lesions. ❋ Jochen Schulze Et Al. (2010)
(C) Xray analysis (top, scale bars, 1 mm) and µCT scanning (bottom, scale bars, 2 mm) demonstrating the presence of osteolytic lesions in 52 weeks old female ❋ Jochen Schulze Et Al. (2010)
DKK1 mutations on bone mass in humans, there is hallmark evidence for an over-production of DKK1 in human cancer cells being responsible for the development of osteolytic lesions associated with metastatic bone disease Albeit Dkk1 can inhibit Wnt signalling through a direct interaction with Lrp5 or Lrp6, its antagonistic function is significantly enhanced by members of the Kremen (Krm) family, which serve as high affinity receptors for Dkk proteins ❋ Jochen Schulze Et Al. (2010)
Bu G, Lu W, Liu CC, Selander K, Yoneda T, et al. (2008) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. ❋ Jochen Schulze Et Al. (2010)
Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. ❋ Jochen Schulze Et Al. (2010)
These luciferase-expressing osteosarcomas showed conserved osteolytic and osteogenic activities in mice and were detectable by in vivo bioluminescence imaging. ❋ J Rousseau (2010)
A "non-inflammatory" type showing predominantly osteolytic destruction with little disc space narrowing and sclerosis. ❋ Unknown (2010)
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. ❋ Jochen Schulze Et Al. (2010)
Slide 19: Methodology Dosimetry • The accumulation of radiopharmaceuticals is much higher in osteoblastic than in osteolytic metastases, with ratios of 1: 15 and 1: 3, respectively. ❋ Unknown (2009)
- Fractures resulting in considerable morbidity - Hypercalcemic syndrome due to increased bone resorption of osteolytic metastases - paraneoplastic syndrome. ❋ Unknown (2009)
In one case, Anselmetti recounted, a 79-year-old Roman Catholic nun had severe pain and was bedridden because of cancerous osteolytic lesions (thyroid cancer metastases) located deep in her pelvis-previously treated unsuccessfully with chemotherapy and radiotherapy. ❋ Unknown (2009)
In one case, Anselmetti recounted, a 79-year-old Roman Catholic nun had severe pain and was bedridden because of cancerous osteolytic lesions (thyroid cancer metastases) located deep in her pelvis -- previously treated unsuccessfully with chemotherapy and radiotherapy. ❋ Unknown (2009)
Generic Aredia® is indicated in the treatment of hypercalcemia of malignancy, paget's disease, osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. ❋ Unknown (2009)
Acceleron's lead program, ACE-011, is currently in Phase II studies in multiple myeloma patients with osteolytic bone disease. ❋ Unknown (2009)
A Phase 2 clinical study in multiple myeloma patients with osteolytic bone disease is ongoing. ❋ Unknown (2009)
Acceleron and Celgene Corporation are co-developing ACE-011 which is currently being evaluated in a Phase 2 clinical study of multiple myeloma patients with osteolytic bone disease. ❋ Unknown (2009)
